Recent biotech IPOs Iambic Therapeutics and City Therapeutics saw significant price jumps, rising 25.9% and 22.2% respectively after their market debuts, raising substantial capital. Inverse leveraged ETFs SMCZ and SMST also gained sharply as their underlying stocks declined, offering investors a way to profit from falling stock prices. These moves highlight investor interest in both new biotech opportunities and strategic ETF plays amid market fluctuations.
The recent rally of Iambic, City Therapeutics, and Inverse ETFs is presented here with Pluang's health sector market data for context. For readers following health stocks, as of Oct 17, 2026 04:11 WIB, out of 150 priced US health-sector stocks on Pluang, 44 rose and 106 fell. Notably, NVAX declined by 12.79% to USD 11.18 with a typical hold time of 59 days and a Pluang order activity skewed 67% Buy, contrasting with DNA which fell 12.67% to USD 10.27 and had a shorter hold time of 8 days and a 68% Sell order activity.
Strawberry Fields REIT announced a cash dividend of $0.17 per common share for the fourth quarter of 2026. The dividend will be paid on December 30, 2026, to shareholders recorded by December 16, 2026. The company specializes in owning and leasing he...
Bragar Eagel & Squire, P.C. is investigating Fervo Energy Company for potential securities law violations following a significant stock price drop after the company disclosed operational problems at its pilot plant. Issues include transmission curtai...
Ready Capital Corporation reported a GAAP loss per share of $0.40 and a distributable loss per share of $0.53 for Q3 2026. The company retired all its 2026 corporate debt maturities, including $350 million of senior secured notes, and issued $225 mil...
Gran Tierra Energy reported a Q3 2026 net loss of $42 million, impacted by lower production in Colombia and increased transportation costs due to border closures. The company ended the quarter with $141 million in cash and $53 million in undrawn cred...
Blue Owl Technology Finance (OTF) shares trade at a steep 41% discount to net asset value due to market worries over credit quality and dividend coverage. Non-accrual loans rose slightly to 1.1%, mainly from Signifyd's preferred stock, but remain low...
